Cerus (NASDAQ:CERS) announced its quarterly earnings results on Thursday. The biotechnology company reported ($0.13) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.01), Briefing.com reports. The company had revenue of $18.20 million during the quarter, compared to the consensus estimate of $17.55 million. Cerus had a negative net margin of 98.69% and a negative return on equity of 81.46%. The business’s revenue was up 18.2% on a year-over-year basis. During the same quarter in the prior year, the firm posted ($0.10) earnings per share. Cerus updated its FY 2019 guidance to EPS.
Shares of Cerus stock traded down $0.51 during trading hours on Friday, reaching $5.34. The company’s stock had a trading volume of 1,647,833 shares, compared to its average volume of 878,786. The business’s 50 day simple moving average is $5.35. Cerus has a one year low of $4.49 and a one year high of $8.05. The company has a debt-to-equity ratio of 0.85, a quick ratio of 2.50 and a current ratio of 2.83. The stock has a market cap of $806.34 million, a PE ratio of -12.14 and a beta of 1.60.
A number of research firms have recently weighed in on CERS. BidaskClub upgraded shares of Cerus from a “hold” rating to a “buy” rating in a report on Wednesday. ValuEngine upgraded shares of Cerus from a “hold” rating to a “buy” rating in a report on Tuesday, July 23rd. Finally, Zacks Investment Research downgraded shares of Cerus from a “hold” rating to a “sell” rating in a report on Wednesday, July 10th.
In other Cerus news, insider William Mariner Greenman bought 10,000 shares of Cerus stock in a transaction dated Tuesday, June 4th. The shares were purchased at an average cost of $4.60 per share, for a total transaction of $46,000.00. Following the acquisition, the insider now directly owns 638,485 shares in the company, valued at approximately $2,937,031. The acquisition was disclosed in a filing with the SEC, which is accessible through the SEC website. Insiders own 7.26% of the company’s stock.
Institutional investors have recently bought and sold shares of the company. Swiss National Bank boosted its holdings in Cerus by 3.0% during the second quarter. Swiss National Bank now owns 254,800 shares of the biotechnology company’s stock worth $1,432,000 after buying an additional 7,500 shares in the last quarter. Stephens Inc. AR boosted its holdings in Cerus by 18.5% during the second quarter. Stephens Inc. AR now owns 909,320 shares of the biotechnology company’s stock worth $5,110,000 after buying an additional 141,707 shares in the last quarter. DekaBank Deutsche Girozentrale boosted its holdings in Cerus by 421.7% during the second quarter. DekaBank Deutsche Girozentrale now owns 240,000 shares of the biotechnology company’s stock worth $1,186,000 after buying an additional 194,000 shares in the last quarter. Aperio Group LLC purchased a new stake in Cerus during the second quarter worth $27,000. Finally, ARK Investment Management LLC boosted its holdings in Cerus by 11.2% during the second quarter. ARK Investment Management LLC now owns 8,493,022 shares of the biotechnology company’s stock worth $47,731,000 after buying an additional 853,589 shares in the last quarter. Hedge funds and other institutional investors own 66.21% of the company’s stock.
Cerus Corporation, a biomedical products company, focuses on developing and commercializing the INTERCEPT Blood System to enhance blood safety. Its INTERCEPT Blood System, a proprietary technology for controlling biological replication that is designed to reduce blood-borne pathogens in donated blood components intended for transfusion.
Read More: Why does the United States have a lingering trade deficit?
Receive News & Ratings for Cerus Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cerus and related companies with MarketBeat.com's FREE daily email newsletter.